Precipio (NASDAQ:PRPO) Announces Earnings Results

Precipio (NASDAQ:PRPO) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $7.02 million during the quarter. Precipio had a negative net margin of 3.57% and a negative return on equity of 6.73%.

Precipio Price Performance

Precipio stock traded up $0.29 during mid-day trading on Friday, hitting $23.50. 75,806 shares of the company were exchanged, compared to its average volume of 42,911. Precipio has a 12-month low of $13.80 and a 12-month high of $33.63. The company has a market capitalization of $42.06 million, a P/E ratio of -50.00 and a beta of 1.30. The business’s 50 day simple moving average is $23.42 and its two-hundred day simple moving average is $25.03. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.56 and a quick ratio of 1.33.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PRPO shares. Wall Street Zen lowered shares of Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new stake in shares of Precipio during the 3rd quarter worth about $194,000. Geode Capital Management LLC grew its holdings in shares of Precipio by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock worth $377,000 after buying an additional 789 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Precipio by 10.7% in the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock valued at $333,000 after buying an additional 1,400 shares during the last quarter. Institutional investors and hedge funds own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.